LEVEL 4 R01AX06

Δραστικές

MUPIROCIN

Φάρμακα

  • DRUGBANK - Mupirocin
  • indication:

    For the treatment of <i>Staphylococci</i> nasal carriers.

  • pharmacology:

  • mechanism:

    Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, an enzyme which promotes the conversion of isoleucine and tRNA to isoleucyl-tRNA. Prevention of this enzymes from functioning properly results in the inhibition of bacterial protein and RNA synthesis.

  • toxicity:

  • absorprion:

    No measurable systemic absorption

  • halflife:

    20 to 40 minutes

  • roouteelimination:

    Following the application of Centany (mupirocin ointment),2% to a 400 cm2 area on the back of 23 healthy volunteers once daily for 7 days, the mean (range) cumulative urinary excretion of monic acid over 24 hrs following the last administration was 1.25% (0.2% to 3.0%) of the administered dose of mupirocin.

  • volumedistribution:

  • clearance: